The programme ensures that people who have undergone a bone marrow transplant can access the Home Transplant Programme (PTD), even if they do not have a caregiver within their family environment.
The project is made possible thanks to the support of Kern Pharma and the “la Caixa” Foundation, which have contributed to its development and continuity. The pilot phase also received financial support from Caritas Diocesana de Barcelona.
A pioneering model to ensure equitable access to the PTD
Bone marrow transplantation is a treatment indicated for serious haematological diseases and requires an intensive recovery period lasting approximately two weeks.
The Clínic’s PTD allows this recovery period to take place at home, with daily follow-up by the Home Care Unit (UAD), which celebrated its 25th anniversary this year. Before the project was created, patients without a family caregiver were excluded from the programme, resulting in longer hospital stays and unequal access to care.
To address this issue, Recovering Lives, Preventing Social Exclusion incorporates professional caregivers who receive specialised training provided by the UAD through the Training and Work Foundation and offer support at home during the recovery period. This model guarantees safe and personalised care while also creating employment opportunities for people in vulnerable situations.
Six years of impact: patient care and employment inclusion
Between 2019 and 2025, the project supported 61 patients through different home-care modalities, including a continuous 24-hour service for fifteen days. At the same time, 49 caregivers participated in the programme, with a stable team of nine professionals trained by the UAD and reinforced with new recruits according to annual needs.
The project’s social impact is significant: 89% of caregivers secured stable employment after completing the programme, mainly in home-care services or other care-related positions. This result consolidates the project as an initiative that combines healthcare and social benefits, supporting both patient recovery and the labour market integration of vulnerable groups.
Regarding service quality, 2024 evaluations showed 100% patient satisfaction, with patients highlighting professionalism, hygiene care, the sense of safety and the emotional support received. Caregivers also rated their experience very positively: 95% gave the highest possible score to the training, guidance and impact on their professional development.
Scientific recognition and international outreach
In 2024, the project received the INNOVA-H First Prize, an award from the National Haematology Congress that recognises healthcare innovation initiatives with a real impact on patients’ quality of life.
The jury particularly highlighted the integrative nature of the model, which combines specialised home care with employment inclusion, as well as its ability to reduce inequalities in access to the PTD.
The project was also selected for an oral presentation at the World Hospital at Home Congress, held in Vienna in 2025, further strengthening its international visibility and its potential as a reproducible and scalable model.
